Marcia Belvin Biography and Net Worth

Dr. Belvin joined CytomX in 2018. Prior to this, Dr. Belvin held roles of increasing responsibility at Genentech where, for over 13 years, she led multiple preclinical pipeline teams and oversaw programs in cancer signaling, cancer metabolism, and cancer immunology. Dr. Belvin began her career at Exelixis where she managed teams responsible for preclinical pipeline discovery within the oncology and inflammation portfolios. Dr. Belvin received her B.A. degree from Harvard University and her Ph.D. from the University of California, Berkeley. Dr. Belvin also trained at the Dana-Farber Cancer Institute and Cold Spring Harbor Laboratory.

What is Marcia Belvin's net worth?: The estimated net worth of Marcia Belvin is at least $1.39 million as of March 18th, 2025. Belvin owns 248,636 shares of CytomX Therapeutics stock worth more than $1,389,875 as of February 24th. This net worth approximation does not reflect any other assets that Belvin may own. Learn More about Marcia Belvin's net worth.
How do I contact Marcia Belvin?: The corporate mailing address for Belvin and other CytomX Therapeutics executives is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. CytomX Therapeutics can also be reached via phone at (605) 515-3185 and via email at [email protected]. Learn More on Marcia Belvin's contact information.
Has Marcia Belvin been buying or selling shares of CytomX Therapeutics?: Marcia Belvin has not been actively trading shares of CytomX Therapeutics during the last quarter. Most recently, Marcia Belvin sold 19,512 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a transaction totalling $11,707.20. Following the completion of the sale, the senior vice president now directly owns 248,636 shares of the company's stock, valued at $149,181.60. Learn More on Marcia Belvin's trading history.
Who are CytomX Therapeutics' active insiders?: CytomX Therapeutics' insider roster includes Marcia Belvin (SVP), Sean McCarthy (CEO), Christopher Ogden (CFO), and Lloyd Rowland (General Counsel). Learn More on CytomX Therapeutics' active insiders.
Are insiders buying or selling shares of CytomX Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 79,947 shares worth more than $47,968.20. The most recent insider tranaction occured on March, 18th when CEO Sean A Mccarthy sold 37,656 shares worth more than $22,593.60. Insiders at CytomX Therapeutics own 6.6% of the company. Learn More about insider trades at CytomX Therapeutics.
Information on this page was last updated on 3/18/2025.

Marcia Belvin Insider Trading History at CytomX Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2025	Sell	19,512	$0.60	$11,707.20	248,636
12/20/2023	Sell	4,077	$1.38	$5,626.26	155,124
9/22/2023	Sell	4,119	$1.30	$5,354.70	147,951

Marcia Belvin Buying and Selling Activity at CytomX Therapeutics

CytomX Therapeutics Company Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Today's Range

Now: $5.44

$5.44

$5.74

50 Day Range

MA: $4.97

$3.88

$6.09

2 Week Range

Now: $5.44

$0.40

$6.35

Volume

1,890,436 shs

Average Volume

3,280,351 shs

Market Capitalization

$921.73 million

P/E Ratio

13.60

Dividend Yield

N/A

Beta

2.44